Last SFr.169.90 CHF
Change Today -0.10 / -0.06%
Volume 10.3K
COPN On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
As of 11:43 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

cosmo pharmaceuticals spa (COPN) Snapshot

Open
SFr.170.00
Previous Close
SFr.170.00
Day High
SFr.170.00
Day Low
SFr.166.80
52 Week High
07/9/14 - SFr.193.70
52 Week Low
10/1/13 - SFr.60.00
Market Cap
2.5B
Average Volume 10 Days
20.1K
EPS TTM
SFr.5.69
Shares Outstanding
15.0M
EX-Date
04/28/14
P/E TM
24.7x
Dividend
SFr.1.01
Dividend Yield
0.72%
Current Stock Chart for COSMO PHARMACEUTICALS SPA (COPN)

Related News

No related news articles were found.

cosmo pharmaceuticals spa (COPN) Related Businessweek News

No Related Businessweek News Found

cosmo pharmaceuticals spa (COPN) Details

Cosmo Pharmaceuticals S.p.A. operates as a specialty pharmaceutical company primarily in Italy. The company develops, licenses, and commercializes proprietary pharmaceutical products, primarily for the treatment of inflammatory bowel diseases, colon infections, and other colon diseases, as well as topically treated skin disorders; and manufactures pharmaceutical products for third parties and provides related services. Its products comprise Lialda, Mezavant, and Mesavancol proprietary formulations for mild to moderate ulcerative colitis; Zacol NMX for intestinal disorders; Uceris and Cortiment products for ulcerative colitis; and Low Molecular Weight Heparin MMX for the treatment of Ulcerative Colitis. The company also develops various products, including Rifamycin SV MMX, which is under Phase III clinical trials and is intended for use as an antibiotic; CB-03-01, a steroidal ester, androgen antagonist that is under Phase II clinical trials; CB-17-01, a coloring agent that is used to stain the mucosa to discover pre-cancerous lesions and polyps in the colon and has completed Phase II clinical trials; and CB-01-16, which is under Phase I clinical trials and is intended for the treatment of opioid induced constipation. It has a strategic collaboration agreement with Santarus Inc. The company is headquartered in Lainate, Italy.

179 Employees
Last Reported Date: 07/30/14

cosmo pharmaceuticals spa (COPN) Top Compensated Officers

Founder and Chairman
Total Annual Compensation: €750.0K
Chief Financial Officer, Head of Investor Rel...
Total Annual Compensation: €328.5K
Compensation as of Fiscal Year 2013.

cosmo pharmaceuticals spa (COPN) Key Developments

Cosmo Pharmaceuticals S.p.A. Reports Consolidated Financial Results for the Half Year Ended June 30, 2014

Cosmo Pharmaceuticals S.p.A. reported consolidated financial results for the half year ended June 30, 2014. For the half year, revenue was EUR 41.1 million against EUR 26.6 million a year ago. Operating result was EUR 14.6 million against EUR 6.7 million a year ago. Profit before taxes was EUR 79.4 million against EUR 64.9 million a year ago. Profit after taxes was EUR 76.8 million against EUR 63.3 million a year ago. Profit per basic share was EUR 5.32 against EUR 4.51 a year ago. Net operating revenues increased by 54.6%, driven by a 104% increase in royalties to EUR 14.8 million (EUR 5.9 million from Lialda®/Mezavant®/Mesavancol® and EUR 8.9 million from Uceris®/Cortiment®), a 96.9% increase in the manufacturing of MMX® products and a 9.4% increase in manufacturing of generic products and specialty drugs for third parties.

Cosmo Pharmaceuticals S.p.A., H1 2014 Earnings Call, Jul 30, 2014

Cosmo Pharmaceuticals S.p.A., H1 2014 Earnings Call, Jul 30, 2014

Cosmo Pharmaceuticals S.p.A. - Analyst/Investor Day

To discuss in its definitive merger agreement with Cosmo Technologies Limited

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COPN:SW SFr.169.90 CHF -0.10

COPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $45.33 USD -1.40
Depomed Inc $15.03 USD +0.31
Durect Corp $1.52 USD -0.03
Supernus Pharmaceuticals Inc $7.99 USD -0.20
Veloxis Pharmaceuticals A/S kr1.95 DKK +0.04
View Industry Companies
 

Industry Analysis

COPN

Industry Average

Valuation COPN Industry Range
Price/Earnings 23.3x
Price/Sales 26.5x
Price/Book 10.8x
Price/Cash Flow 24.1x
TEV/Sales 26.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COSMO PHARMACEUTICALS SPA, please visit www.cosmopharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.